Protective effects of norursodeoxycholic acid versus ursodeoxycholic acid on thioacetamide-induced rat liver fibrosis

Journal of Clinical and Experimental Hepatology

Volumn 4, Issue 4, 2014, Pages 293-301

  Buko, Vyacheslav U ^a,b   Lukivskaya, Oxana Y ^a   Naruta, Elena E ^a   Belonovskaya, Elena B ^a   Tauschel, Horst Dietmar ^c  

^a INSTITUTE OF BIOCHEMISTRY   (Belarus)

^b School of Medical Sciences   (Poland)

^c Dr Falk Pharma GmbH   (Germany)

Author keywords

Fibrosis; Liver; Norursodeoxycholic acid; Thioacetamide; Ursodeoxycholic acid

Indexed keywords

COLLAGEN TYPE 4; HYDROXYPROLINE; NORURSODEOXYCHOLIC ACID; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; THIOACETAMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; LIVER FIBROSIS; LIVER PROTECTION; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; REMISSION;

EID: 84920857409     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.02.001     Document Type: Article

References (31)

1. Angulo P., Batts K.P., Therneau T.M., Jorgensen R.A., Dickson E.R., Lindor K.D. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999, 29:644-647.
2. Poupon R.E., Lindor K.D., Cauch-Dudek K., Dickson E.R., Poupon R., Heathcote E.J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884-890.
3. Corpechot C., Carrat F., Bonnand A.M., Poupon R.E., Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32:1196-1199.
4. He H., Mennone A., Boyer J.L., Cai S.Y. Combination of retinoic acidand ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology 2011, 53:548-557.
5. Mas N., Tasci I., Comert B., Ocal R., Mas M.R. Ursodeoxycholic acid treatment improves hepatocyte ultrastructure in rat liver fibrosis. World J Gastroenterol 2008, 14:1108-1111.
6. Stenner J.M.C., Jazrawi R.P., Ahmed H.A., Verna A., Northfield T.C. The effect of ursodeoxycholic acid on fibrosis markers in alcoholic liver diseases. Liver Cirrhosis and its Development 2001, 229-235. Kluwer Academic Publishers, Dordrecht-Boston-London. Boyer (Ed.).
7. Buko V.U., Lukivskaya O., Zavodnik L.B., Sadovnichy V.V., Petushok N.E., Tauschel H.-D. Antioxidative effect of ursodeoxycholic acid in the liver of rats with oxidative stress caused by gamma-irradiation. Ukr Biokhim Zh 2002, 74:88-93.
8. Ljubuncic P., Tanne Z., Bomzon A. Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease. Dig Dis Sci 2000, 45:1921-1928.
9. Buko V.U., Kuzmitskaya-Nikolaeva A., Naruta E.E., Lukivskaya O.Y., Kirko S.N., Tauschel H.D. Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine and choline. Hepatol Res 2011, 41:647-659.
10. Neuman M.G., Shear N.H., Bellentani S., Tiribelli C. Role of cytokines in ethanol-induced cytotoxicity invitro in Hep G2 cells. Gastroenterology 1998, 115(1):157-166.
11. Beraza N., Ofner-Ziegenfuss L., Ehedego H., et al. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut 2011, 60:387-396.
12. Fickert P., Wagner M., Marschall H.U., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006, 130(2):465-481.
13. Sombetzky M., Fickert P., Loeberman M., et al. 24-nor-ursodeoxycholic acid as novel therapeutic strategy for inflammation-induced liver fibrosis in a murine model of Shisostoma mansoni infection. JHepatol 2008, 48(suppl 2):21-22.
14. Fickert P., Pollheimer M.J., Silbert D., et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. JHepatol 2013, 58:1201-1208.
15. Tsukamoto H., Matsuoka M., French S.W. Experimental models of liver fibrosis. Semin Liver Dis 1990, 110:56-65.
16. Patsenker E., Popov Y., Stickel F., et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009, 50(5):1501-1511.
17. Lukivskaya O., Patsenker E., Lis R., Buko V.U. Inhibition of inducible nitric oxide synthase activity prevents liver recovery in rat thioacetamide-induced fibrosis reversal. Eur J Clin Invest 2008, 38:317-325.
18. Cho J.J., Hocher B., Herbst H., et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000, 118:1169-1178.
19. Li X., Benjamin I.S., Alexander B. Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality. JHepatol 2002, 36:488-493.
20. Müller A., Machnik F., Zimmermann T., Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats-usefulness and reliability of this animal model. Exp Pathol 1988, 34:229-236.
21. Akahoshi T., Hashizume M., Tanoue K., et al. Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor beta-1. Gastroenterol Hepatol 2002, 17:59-65.
22. Tasci I., Mas M.R., Vural S.A., et al. Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery. Liver Int 2006, 26:261-268.
23. Zhang L.X., Liang T.J., Tan Y.R., et al. Protective effects of ursodeoxycholic acid against immune-mediated liver fibrosis in rats. Hepatogastroenterology 2010, 57:1196-1202.
24. Yang H., Ramani K., Xia M., et al. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology 2009, 49:1982-1991.
25. Poo J.L., Feldmann G., Erlinger S., et al. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Gastroenterology 1992, 102:1752-1759.
26. Cohen B.I., Hofmann A.F., Mosbach E.H., et al. Differing effect of nor-ursodeoxycholic and ursodeoxycholic acid on hepatic histology and bile acid metabolism in rabbit. Gastroenterology 1986, 91:189-197.
27. Popov Y., Patsenker E., Fickert P., Trauner M., Schuppan D. Mdr2 (Abcb4)/ mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. JHepatol 2005, 43:1045-1054.
28. Halilbasic E., Fiorotto R., Fickert P., et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2/mice. Hepatology 2009, 49:1972-1981.
29. Yeh C.N., Maitra A., Lee K.F., Jan Y.Y., Chen M.F. Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 2004, 25:631-636.
30. Schuppan D., Popov Y. Rationale and targets for antifibrotic therapies. Gastroenterol Clin Biol 2009, 33:949-957.
31. Popov Y. Mouse model of primary biliary cirrhosis with progressive fibrosis: are we there yet?. Hepatology 2013, 57(2):429-431.